Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an update.
China Resources Pharmaceutical has disclosed key first‑quarter 2026 figures from subsidiary Tasly Pharmaceutical, which reported unaudited revenue of RMB2.16 billion and net profit of RMB364.6 million, both higher than a year earlier. Tasly’s total assets edged up to RMB15.69 billion while liabilities were largely stable, but the company booked a sharp net cash outflow, leaving cash and equivalents at RMB598.4 million at the end of March.
The results, prepared under PRC GAAP and not yet reviewed by China Resources Pharmaceutical’s auditors, apply only to Tasly and do not provide a full picture of the group’s overall performance. The parent has urged shareholders and potential investors to treat the numbers with caution when trading its securities and to refer to Tasly’s full quarterly filing on the Shanghai Stock Exchange for more detailed financial information.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical conglomerate with a broad portfolio spanning manufacturing, distribution and related healthcare services. Through its non‑wholly‑owned subsidiary China Resources Sanjiu Medical & Pharmaceutical, it holds about 28% of Shanghai‑listed Tasly Pharmaceutical Group, which is treated as a subsidiary in the group’s consolidated accounts.
Average Trading Volume: 18,740,562
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$36.69B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.